EMD-4539

Single-particle
3.6 Å
EMD-4539 Deposition: 08/01/2019
Map released: 27/02/2019
Last modified: 13/11/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-4539

Nanodisc reconstituted human ABCB1 in complex with UIC2 fab and taxol

EMD-4539

Single-particle
3.6 Å
EMD-4539 Deposition: 08/01/2019
Map released: 27/02/2019
Last modified: 13/11/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Mus musculus, Homo sapiens
Sample: Nanodisc reconstituted human ABCB1 in complex with UIC2 Fab and taxol
Fitted models: 6qex (Avg. Q-score: 0.392)

Deposition Authors: Alam A , Locher KP
Structural insight into substrate and inhibitor discrimination by human P-glycoprotein.
Alam A , Kowal J , Broude E, Roninson I , Locher KP
(2019) Science , 363 , 753 - 756
PUBMED: 30765569
DOI: doi:10.1126/science.aav7102
ISSN: 1095-9203
ASTM: SCIEAS
Abstract:
ABCB1, also known as P-glycoprotein, actively extrudes xenobiotic compounds across the plasma membrane of diverse cells, which contributes to cellular drug resistance and interferes with therapeutic drug delivery. We determined the 3.5-angstrom cryo-electron microscopy structure of substrate-bound human ABCB1 reconstituted in lipidic nanodiscs, revealing a single molecule of the chemotherapeutic compound paclitaxel (Taxol) bound in a central, occluded pocket. A second structure of inhibited, human-mouse chimeric ABCB1 revealed two molecules of zosuquidar occupying the same drug-binding pocket. Minor structural differences between substrate- and inhibitor-bound ABCB1 sites are amplified toward the nucleotide-binding domains (NBDs), revealing how the plasticity of the drug-binding site controls the dynamics of the adenosine triphosphate-hydrolyzing NBDs. Ordered cholesterol and phospholipid molecules suggest how the membrane modulates the conformational changes associated with drug binding and transport.